BioLife Solutions (BLFS) to Release Quarterly Earnings on Monday

BioLife Solutions (NASDAQ:BLFSGet Rating) will post its quarterly earnings results after the market closes on Monday, May 9th. Analysts expect BioLife Solutions to post earnings of ($0.13) per share for the quarter. BioLife Solutions has set its FY 2022 guidance at EPS.

BioLife Solutions (NASDAQ:BLFSGet Rating) last posted its quarterly earnings results on Monday, February 28th. The medical equipment provider reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.25). BioLife Solutions had a negative return on equity of 5.19% and a negative net margin of 7.04%. The company had revenue of $37.30 million for the quarter, compared to analysts’ expectations of $37.28 million. During the same period in the prior year, the business earned ($0.01) EPS. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Shares of NASDAQ BLFS traded up $0.21 on Tuesday, hitting $13.39. The company had a trading volume of 2,665 shares, compared to its average volume of 395,712. BioLife Solutions has a 12-month low of $12.13 and a 12-month high of $60.67. The company has a 50 day moving average price of $20.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.12 and a quick ratio of 2.41. The firm has a market cap of $563.72 million, a price-to-earnings ratio of -62.76 and a beta of 2.01.

In other BioLife Solutions news, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 2nd. The shares were sold at an average price of $29.88, for a total value of $298,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Rice sold 16,670 shares of the stock in a transaction that occurred on Thursday, February 3rd. The shares were sold at an average price of $27.84, for a total transaction of $464,092.80. The disclosure for this sale can be found here. Insiders have sold a total of 178,090 shares of company stock valued at $3,682,142 over the last three months. Corporate insiders own 5.90% of the company’s stock.

A number of hedge funds have recently made changes to their positions in BLFS. Parametric Portfolio Associates LLC raised its stake in BioLife Solutions by 33.4% during the 4th quarter. Parametric Portfolio Associates LLC now owns 42,435 shares of the medical equipment provider’s stock valued at $1,582,000 after buying an additional 10,618 shares during the last quarter. Jane Street Group LLC purchased a new position in BioLife Solutions during the third quarter valued at approximately $1,417,000. Alliancebernstein L.P. lifted its holdings in BioLife Solutions by 30.5% during the fourth quarter. Alliancebernstein L.P. now owns 35,069 shares of the medical equipment provider’s stock valued at $1,307,000 after purchasing an additional 8,189 shares in the last quarter. Squarepoint Ops LLC purchased a new position in BioLife Solutions during the fourth quarter valued at approximately $962,000. Finally, Glenmede Trust Co. NA lifted its holdings in BioLife Solutions by 3.6% during the fourth quarter. Glenmede Trust Co. NA now owns 25,403 shares of the medical equipment provider’s stock valued at $946,000 after purchasing an additional 888 shares in the last quarter. 83.48% of the stock is currently owned by institutional investors.

BLFS has been the topic of a number of research reports. StockNews.com raised shares of BioLife Solutions to a “sell” rating in a report on Friday, March 25th. TheStreet lowered BioLife Solutions from a “c-” rating to a “d” rating in a research note on Tuesday, April 12th. B. Riley reduced their price objective on BioLife Solutions from $67.00 to $48.00 in a research note on Wednesday, March 2nd. Oppenheimer upgraded shares of BioLife Solutions from a “market perform” rating to an “outperform” rating in a report on Monday, April 25th. Finally, Zacks Investment Research lowered BioLife Solutions from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 3rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $58.50.

About BioLife Solutions (Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Featured Articles

Earnings History for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.